Cargando…
Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, ther...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332938/ https://www.ncbi.nlm.nih.gov/pubmed/28134806 http://dx.doi.org/10.3390/cancers9020015 |